In the past decades, the armamentarium for the systemic treatment of advanced HCC was limited to the anti-vascular endothelial growth factor (VEGFR), multi-target-tyrosine kinase inhibitor (TKI) sorafenib. The gene discussed is KDR; the disease is hepatocellular carcinoma.